Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year
- PMID: 189724
- DOI: 10.1001/archpsyc.1977.01770130045004
Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year
Abstract
In a simple remitted, nonpsychotic schizophrenics, the relapse rate within one year was significantly higher for those patients taking placebo as opposed to those taking fluphenazine hydrochloride orally or fluphenazine decanoate. There were no differences in relapse rates between the two active drugs, but there were significantly more terminations due to toxicity from fluphenazine decanoate than from pluphenazine given orally, entirely due to the fact that in 35% of patients receiving fluphenazine decanoate, severe akinesia developed.
Similar articles
-
Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.Arch Gen Psychiatry. 1977 Oct;34(10):1215-9. doi: 10.1001/archpsyc.1977.01770220097011. Arch Gen Psychiatry. 1977. PMID: 199129 Clinical Trial.
-
Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].Psychopharmacol Bull. 1977 Apr;13(2):49-50. Psychopharmacol Bull. 1977. PMID: 323910 Clinical Trial. No abstract available.
-
Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.Arch Gen Psychiatry. 1979 Nov;36(12):1283-94. doi: 10.1001/archpsyc.1979.01780120013001. Arch Gen Psychiatry. 1979. PMID: 227340 Clinical Trial.
-
Depot fluphenazine: risk/benefit ratio.J Clin Psychiatry. 1984 May;45(5 Pt 2):28-35. J Clin Psychiatry. 1984. PMID: 6370986 Review.
-
The use of depot neuroleptics: clinical experience in the United States.J Clin Psychiatry. 1984 May;45(5 Pt 2):5-12. J Clin Psychiatry. 1984. PMID: 6370987 Review.
Cited by
-
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Schizophr Res Treatment. 2012;2012:407171. doi: 10.1155/2012/407171. Epub 2012 Feb 15. Schizophr Res Treatment. 2012. PMID: 22966436 Free PMC article.
-
Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts.Schizophr Bull Open. 2022 Oct 18;3(1):sgac058. doi: 10.1093/schizbullopen/sgac058. eCollection 2022 Jan. Schizophr Bull Open. 2022. PMID: 39144771 Free PMC article.
-
Do neuroleptics prevent relapse? Clinical observations in a psychosocial rehabilitation program.Psychiatr Q. 1986-1987 Spring;58(1):42-50. doi: 10.1007/BF01064038. Psychiatr Q. 1986. PMID: 2879301 No abstract available.
-
Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review.BJPsych Open. 2018 Jun 29;4(4):215-225. doi: 10.1192/bjo.2018.17. eCollection 2018 Jul. BJPsych Open. 2018. PMID: 29988997 Free PMC article. Review.
-
Fluphenazine (oral) versus placebo for schizophrenia.Cochrane Database Syst Rev. 2018 Jun 12;6(6):CD006352. doi: 10.1002/14651858.CD006352.pub3. Cochrane Database Syst Rev. 2018. PMID: 29893410 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources